Sharemaestro Newsreel

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

Suha Jhaveri, Bill Warren and Jim Wassil added to ILiAD Board of Directors; Antony Blanc appointed Chief Business Officer Appointments deepen vaccine development expertise and enhance global commercial and strategic leadership WESTON, Fla., August 11, 2026--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage …

Hims & Hers Health Earnings: What To Look For From HIMS

Hims & Hers Health Earnings: What To Look For From HIMS Telehealth company Hims & Hers Health (NYSE:HIMS) will be announcing earnings results this Monday after market hours. Here's what to expect. Hims & Hers Health missed analysts' revenue expectations last quarter, reporting revenues …

Humana Healthy Horizons in Indiana Collaborates with HealthStream to Expand and Strengthen Home Care Workforce

Certification Scholarships and Innovative Retention Program Address Critical Health Need INDIANAPOLIS, August 11, 2026--(BUSINESS WIRE)--Humana Healthy Horizons in Indiana, Humana's Medicaid managed care plan, is collaborating with HealthStream (Nasdaq: HSTM), a leading healthcare technology platform company for clinical workforce solutions, to improve the lives …

Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices

Updated program delivers simplified savings, greater benefits transparency, and expanded opportunities for practice growth Introduces new rewards opportunities for customer segments, including first-time APP members, growing practices, and long-standing loyal customers IRVINE, Calif., Aug. 11, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today …

Cardinal Health (CAH) Q4 Earnings Beat Estimates

Cardinal Health (CAH) came out with quarterly earnings of $2.91 per share, beating the Zacks Consensus Estimate of $2.42 per share. This compares to earnings of $2.08 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

NVO Crosses Above Average Analyst Target

In recent trading, shares of Novo-Nordisk AS (Symbol: NVO) have crossed above the average analyst 12-month target price of $47.48, changing hands for $47.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on …

Canaccord reitera su calificación de Hims & Hers tras superar previsiones en el Q2

Hims & Hers Q2 2026 earnings: loss despite revenue beat

Hims & Hers Health reported a net loss of $86.3 million in the second quarter of 2026, swinging from net income of $42.5 million in the same period a year earlier, even as revenue climbed 38% to $753.2 million. The company raised its full-year …

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

AbbVie (NYSE: ABBV) is aiming high with its $10.6 billion planned purchase of Apogee Therapeutics (NASDAQ: APGE). The deal, pending regulatory approvals, is expected to close in the third quarter. The move is designed to supplement the pharmaceutical giant's already strong immunology portfolio. However, …

Veeva Vault CRM Selected by Eli Lilly and Company

PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally.Veeva Vault CRM Selected by Eli Lilly and Company Vault CRM is part of the Vault CRM Suite of …

IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test

New test brings quantitative cardiac assessment for cats and dogs into everyday workflows WESTBROOK, Maine, August 11, 2026--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced the launch of the Catalyst™ proBNP Test, the first and only dual-species, …

CEZ Raises 2026 Outlook as Nuclear Output and Power Prices Improve

Czech utility CEZ Group raised its full-year 2026 earnings forecast after reporting a 20% decline in first-half EBITDA as lower realized electricity prices weighed on its generation business. The company now expects full-year EBITDA of CZK 109 billion to CZK 114 billion, while adjusted …

SOLV Q2 Deep Dive: Portfolio Restructuring and ERP Transition Shape Outlook

SOLV Q2 Deep Dive: Portfolio Restructuring and ERP Transition Shape Outlook Healthcare solutions provider Solventum (NYSE:SOLV) reported revenue ahead of Wall Street's expectations in Q2 CY2026, with sales up 2.2% year on year to $2.21 billion. Its non-GAAP profit of $2.55 per share was …

Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific

Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global non-viral transfection reagents market …

Stock futures edge lower as traders focus on Strait of Hormuz reopening

[The New York Stock Exchange on the Wall street sign] Dmitry Vinogradov Stock index futures were lower on Tuesday as traders continued to focus on developments related to the reopening of the Strait of Hormuz. Dow futures (INDU [https://seekingalpha.com/symbol/INDU]) -0.17%, S&P 500 futures (SPX …

New Strong Sell Stocks for August 11th

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Buzzi S.p.A. BZZUF is a building materials company. The Zacks Consensus Estimate for its current year earnings has been revised 10.4% downward over the last 60 days. Group 1 Automotive, …

Eli Lilly's Foundayo Wins UK Approval

(RTTNews) - Eli Lilly and Company's (LLY) oral GLP-1 pill Foundayo has secured UK regulatory approval for weight management and type 2 diabetes, making the UK the first European country to clear the once-daily tablet. The decision by the Medicines and Healthcare products Regulatory …

¿4% Infravalorada? Regeneron Pharmaceuticals (REGN) Tras Sus Resultados Y Recompras

Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S.

OSLO, Norway, August 11, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of the 'Healthcare Resource Utilization and Costs Associated with Blue Light Versus White Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study' in JU Open …

Vertex Pharmaceuticals (VRTX) sube un 11,3 % tras elevar sus previsiones de ingresos para 2026 y revisar al alza sus perspectivas de flujo de caja: ¿ha cambiado el panorama alcista?

Hims & Hers anticipates $880M-$900M Q3 revenue while raising 2026 outlook to $3.1B-$3.3B

Earnings Call Insights: Hims & Hers Health (HIMS) Q2 2026 MANAGEMENT VIEW * "In the second quarter, we welcomed more than 300,000 subscribers, bringing our global subscriber base to nearly 3 million people." (Co-Founder, Chairman & CEO Andrew Dudum) * "In June, we became …

Jim Cramer Recommends Goldman Sachs and Morgan Stanley to Profit From Accelerating M&A Deals

During Mad Money's August 6 episode, host Jim Cramer highlighted why investors should target elite advisory firms rather than speculating on acquisition targets, as he said: Here's a big theme that right now really only impacts two large companies: pent-up demand for mergers and …

Hims & Hers Health Inc (HIMS) (Q2 2026) Earnings Call Highlights: Revenue Surges 40% to ...

This article first appeared on GuruFocus. Revenue: Grew nearly 40% year-over-year to more than $753 million in the second quarter. Subscribers: Added 300,000 net new subscribers, ending the quarter with nearly 3 million. Domestic Revenue: Accelerated to 16% year-over-year growth, generating $622 million. International …

Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed

Tecan Group AG Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed Financial highlights – first half …

Precio de acciones, noticias, cotización e historial de Johnson & Johnson (JNJ.MX)

Unos resultados más sólidos en el segundo trimestre y unas perspectivas más optimistas para 2026 podrían cambiar los argumentos a favor de invertir en DexCom (DXCM)

Rational AG (RATIY) (Q2 2026) Earnings Call Highlights: Record EBIT Margin and Strategic ...

This article first appeared on GuruFocus. Revenue (H1 2026): EUR642 million, up 8% organically and 6% after FX adjustments. Revenue (Q2 2026): EUR324 million, up 4% year-over-year. EBIT (H1 2026): EUR170 million, up 11% year-over-year, with a margin of 26.5% (24.3% excluding tariff refunds). …

OHB SE (WBO:OHB) (Q2 2026) Earnings Call Highlights: Record Backlog and Strategic Growth Amid ...

This article first appeared on GuruFocus. Total Operating Performance: EUR628 million in H1 2026, up from EUR470 million in H1 2024, representing double-digit growth. Adjusted EBITDA: EUR60 million, with a margin of 9.6%, reflecting a 30%+ increase year-on-year. Space Systems Segment Revenue: EUR472 million …

What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders

In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to …

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global patent infringement litigation over lipid nanoparticle (LNP) delivery technology provided Arbutus with …

Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?

It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share (EPS) jumped 18% on a constant exchange rate …

Eli Lilly (LLY) Stock Gets Fair Value Bump After GLP 1 Driven Analyst Revisions

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Eli Lilly's updated fair value price target has shifted from US$1,270.37 to US$1,297.31, giving investors a fresh reference point for how analysts are framing the …

A Mettler-Toledo Director Sold $600,000 in Stock. Here's What Investors Should Know

Key Points The transaction involved the sale of 415 shares at $1,444.62 per share, representing an estimated value of about $599,517 on August 3. The disposition resulted from the immediate sale of shares acquired through the exercise of 415 stock options at a strike …

Mettler-Toledo's CFO Cashed In Options After a Strong Quarter. Here's What to Know

Key Points The disposition involved 2,240 shares at $1,432 per share, totaling about $3.2 million on August 3, 2026. The transaction was structured as a same-day exercise-and-sell involving 2,240 stock options at an exercise price of $595.31. Following the sale, the insider maintains direct …

Abbott vs. Medtronic: Is Consistent Growth Better Than a Turnaround Story?

Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) are both prominent names in the Medtech space. Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped …

Bionano outlines $31M-$33M 2026 revenue forecast amid flow cell supply constraints

Earnings Call Insights: Bionano Genomics (BNGO) Q2 2026 MANAGEMENT VIEW * "Bionano had a strong second quarter, and that strength can be directly attributed to increased adoption by our customers," said (Chairman, Interim CEO, Interim President & Interim Principal Financial Officer Albert Luderer), adding …